Corient Private Wealth LLC Purchases 302,200 Shares of Gossamer Bio, Inc. $GOSS

Corient Private Wealth LLC grew its holdings in Gossamer Bio, Inc. (NASDAQ:GOSS) by 8.9% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,693,683 shares of the company’s stock after purchasing an additional 302,200 shares during the period. Corient Private Wealth LLC owned about 1.62% of Gossamer Bio worth $4,543,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Bank of America Corp DE grew its position in shares of Gossamer Bio by 107.2% in the 4th quarter. Bank of America Corp DE now owns 84,788 shares of the company’s stock valued at $77,000 after acquiring an additional 43,866 shares during the period. Invesco Ltd. bought a new stake in Gossamer Bio in the 1st quarter valued at about $48,000. OMERS ADMINISTRATION Corp acquired a new stake in Gossamer Bio during the first quarter worth approximately $387,000. Cubist Systematic Strategies LLC bought a new position in shares of Gossamer Bio in the first quarter worth $213,000. Finally, Goldman Sachs Group Inc. raised its position in shares of Gossamer Bio by 720.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 939,603 shares of the company’s stock valued at $1,034,000 after buying an additional 825,047 shares in the last quarter. 81.23% of the stock is owned by institutional investors and hedge funds.

Gossamer Bio Trading Up 0.3%

Shares of Gossamer Bio stock opened at $3.44 on Friday. Gossamer Bio, Inc. has a 12-month low of $0.76 and a 12-month high of $3.87. The stock has a fifty day simple moving average of $2.86 and a 200 day simple moving average of $2.32. The company has a market capitalization of $796.22 million, a P/E ratio of -4.99 and a beta of 1.92.

Gossamer Bio (NASDAQ:GOSS) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.02). The firm had revenue of $13.29 million during the quarter, compared to analysts’ expectations of $6.32 million. Gossamer Bio had a negative net margin of 354.50% and a negative return on equity of 1,774.72%. On average, analysts predict that Gossamer Bio, Inc. will post -0.28 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on GOSS. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Gossamer Bio in a research note on Wednesday, October 8th. Cantor Fitzgerald restated an “overweight” rating on shares of Gossamer Bio in a research report on Thursday, September 11th. Finally, Wall Street Zen raised shares of Gossamer Bio from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $8.50.

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.